PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
PureTech Health plc announced that its founded entity, Seaport Therapeutics, appointed Dr. Sharon Mates to its board of directors. Dr. Mates previously served as CEO of Intra-Cellular Therapies, leading the company through its $14.6 billion acquisition by Johnson & Johnson in 2025.
Key figures
- Acquisition value
- $14.6 billion
- Drug sales prior to acquisition
- >$1.5 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.